Evidence map›Paper›PMID 40308488›Full record

ArticleFrontiers in oncology2025

Perinephric myxoid pseudotumor of fat: the first case report in China with an updated literature review.

Yu-Hang Yang, Yue-Ming Zhang, An-Hao Liu, Guang-Cheng Luo, Zheng-Jin Liu, Jian-Wei Xie

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-Hang Yang *Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yue-Ming Zhang *Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
An-Hao Liu *Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Guang-Cheng LuoDepartment of Urology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Zheng-Jin LiuDepartment of Pathology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Jian-Wei XieDepartment of Urology, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The perinephric myxoid pseudotumor of fat (PMPF) is an uncommon benign neoplasm characterized by a favorable prognosis. To date, 21 cases of PMPFs have been reported worldwide, and their detailed characteristics have not been fully elucidated. We report the 22nd case of PMPF, which is the first case in China and happened in a 54-year-old male with a 5.6 cm mass located in the lower inner aspect of the right kidney. The patient underwent a minimally invasive robot-assisted laparoscopic resection of the renal mass. Postoperative histopathological, immunohistochemical, and genetic testing results confirmed the diagnosis of PMPF. No evidence of recurrence was found during a follow-up period of 6 months postoperatively based on clinical and imaging data. This is a report of an unusual case of PMPF with an up-to-date review. According to the latest systematic review and clinical confirmation, PMPF is strongly associated with chronic kidney disease, which is further confirmed by our case. For PMPF, combining imaging methods and immunohistochemical staining is suggested, which may prove beneficial in clinical practice.

Indexed as

diagnosisMDM2pathologyperinephric myxoid pseudotumor of fatrenal disease

Identifiers

PMID40308488
PMCPMC12041072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.